ClinicalTrials.gg
CompletedNCT06866366ReDiPLUSUpdated Oct 7, 2025

Retrospective, Multicenter, Single-arm, Observational Study, With Data From Patients With T2DM With Malnutrition or at Risk, Who Were Prescribed Resource® Diabet Plus as a Hypercaloric and Hyperproteic Specific Formula for Patients With T2DM

An observational study in Malnourished Elderly, Malnourishment and Diabetes Mellitus Type 2, sponsored by Outcomes'10. Completed at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Outcomes'10 · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
59
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Malnutrition with a site in Spain — 14 open to participants now, 15 under way, none of them phase 3. Malnutrition · Spain.

Enrollment
17th of 24
59 · median 219
Started
2025
with 3 others
Observational
24 of 68
5 open now
Registered
61st of 68
by date
Lead sponsor
2 of 68
Outcomes'10

Among the 68 studies in Malnutrition with a site in Spain, this one is the 17th largest by enrollment of the 24 observational ones that give a count, is one of 4 that started in 2025, is one of 24 observational ones, and was the 61st registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

14 of the 68 studies in Malnutrition with a site in Spain are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Malnutrition with a site in Spain, or all of them as a file.
02

Study summary

This retrospective multicentre study aims to provide real-world evidence of the effectiveness of Resource® Diabet Plus as supplementation tool for T2DM patients with malnutrition or at risk of malnutrition, under conditions of routine clinical practice in Spain.

Read the detailed description

Disease-related malnutrition (DRM) is a nutritional imbalance caused by a nutrient deficiency resulting from one or more underlying pathologies. It is the main cause of malnutrition in developed countries, with a prevalence of around 30 million people in Europe in 2020. In Spain, it is estimated that around 20-50% of hospitalized patients suffer from DRM, both in acute and chronic conditions. One of the chronic diseases where malnutrition is associated with higher mortality and increased hospital admissions is Type 2 Diabetes Mellitus (T2DM), particularly in the elderly. T2DM is currently one of the most prevalent chronic diseases worldwide, affecting about 10% of the adult population in 2021. Approximately 90% of diagnosed cases of diabetes are type 2, which is not autoimmune-mediated, unlike type 1 (T1DM). T2DM typically develops over time due to factors such as obesity, sedentary lifestyle, high-calorie diets, and aging. Additionally, malnutrition risk is increased in patients with T2DM, which leads to a poorer prognosis.

For the treatment of DRM in diabetic patients, as in other chronic conditions, clinical guidelines recommend a personalized nutritional plan tailored to the patient's needs and characteristics, primarily focused on increasing dietary calorie intake. If this is insufficient, oral nutritional supplements may be necessary. From a clinical perspective, oral nutritional supplements address malnutrition while offering clinical and functional benefits. In diabetic and malnourished patients, it is crucial to maintain good metabolic and glycemic control, which requires diabetes-specific formulas (DSFs).

Unlike standard formulas, which are typically high in carbohydrates, low in lipids, and lack dietary fiber, DSFs contain carbohydrates with low glycemic indices and also include fiber. The purpose of these formulas is to improve the nutritional status of patients without negatively affecting their glycemic profile, aiming for adequate glycated hemoglobin (HbA1c) levels - values under 7% are generally recommended for this population.

Prospective observational studies in malnourished T2DM patients have shown that supplementation with a DSF for at least 12 weeks improves patients' functional and nutritional status, enhances biochemical markers, and does not increase postprandial glucose levels. Additionally, the use of these formulas benefits glycemic and metabolic control in the short and medium term, potentially improving diabetes management and its associated comorbidities, while reducing long-term complications and mortality.

A retrospective study conducted in 2015 in the Spanish diabetic population suggested that this type of DSF may reduce HbA1c in the medium term, facilitating glycemic control and reducing the negative effects of glycemic fluctuations. This could result in a reduced need for insulin as an antidiabetic treatment.

The existing evidence supports the benefits of DSFs in diabetic patients by helping to maintain metabolic control and improving nutritional, functional, and clinical outcomes. These improvements are associated with fewer hospital visits and admissions. However, more studies are needed to confirm the advantages of using these nutritional formulas specifically designed for diabetic and malnourished patients. Although they are somewhat more expensive than standard supplements, they help patients achieve better metabolic control, which can ultimately lead to lower healthcare costs.

Few retrospective studies have been conducted in the field of nutrition for diabetic and malnourished patients. Most available data come from prospective studies or literature reviews. However, the nature of retrospective real-world studies allows for the assessment of DSF use in a specific population over a relatively short time period, reflecting how malnourished diabetic patients are managed in clinical practice.

This retrospective study aims to provide real-world evidence on the effectiveness of Resource® Diabet Plus supplementation as a DSF in diabetic patients with malnutrition or at risk, under routine clinical practice conditions in Spain.

OBJECTIVES OF THE STUDY

Primary Objective:

- To assess the effects of Resource® Diabet Plus on glycemic control in patients with T2DM who are malnourished or at risk, 12 and 24 weeks after initiation of nutritional therapy.

Secondary Objectives:

  • To assess the effects of Resource® Diabet Plus on metabolic control in malnourished or at-risk T2DM patients at 12 and 24 weeks after treatment initiation.
  • To describe the evolution of nutritional and functional status in T2DM patients who are malnourished or at risk, 12 and 24 weeks after starting Resource® Diabet Plus.
  • To describe the presence of gastrointestinal symptoms in patients treated with Resource® Diabet Plus.
  • To analyze healthcare resource utilization and associated costs after 24 weeks of treatment with Resource® Diabet Plus.

METHODOLOGY

Study Design and Scope:

This is a retrospective, multicenter, single-arm observational study including data from patients at risk of malnutrition identified through validated screening tools or with DRM diagnosed using GLIM criteria, who were prescribed a specific hypercaloric and high-protein formula for diabetic patients: Resource® Diabet Plus. The study will be conducted in the Endocrinology and Nutrition Departments of four Spanish hospitals.

Resource® Diabet Plus must have been prescribed between two years and 24 weeks prior to the study start date. Clinical history data will be collected at the time of prescription (index date, V0), and follow-up data will be collected at 12 weeks (V1) and 24 weeks (V2), allowing a two-week window to adapt to each center's clinical practice. Investigators will have a 3-month window for patient identification and data collection.

Study Product: Resource® Diabet Plus

The study product, Resource® Diabet Plus, is a high-protein and hypercaloric (1.6 kcal/mL) oral nutritional formula with fiber, made from milk protein and 100% soluble fiber. It is suitable for patients with type 1 diabetes, T2DM, or hyperglycemia with increased energy and protein requirements and conditions involving nutritional risk or malnutrition.

Resource® Diabet Plus is presented in 200 mL bottles, each containing:

  • 18 g of protein
  • 5 g of soluble fiber
  • 7.2 g of monounsaturated fatty acids from vegetable oils

Additionally, Resource® Diabet Plus contains slowly absorbed carbohydrates with a glycemic index below 55, making it appropriate for achieving metabolic targets while maintaining glycemic control.

03

Conditions studied

  • Malnourished Elderly
  • Malnourishment
  • Diabetes Mellitus Type 2

Keywords

  • DRM
  • Disease - realted malnutrition
  • Diabetes-specific formula
  • Metabolic control
  • Oral nutritional supplementation
  • DSF
  • T2D
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Type 2 diabetic patient with malnutrition or at risk of malnutrition, treated for it in hospitals of the national network who have been prescribed 1-2 bottles/day of Resource® Diabet Plus

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years.
  • Outpatients or hospitalised patients, at discharge with a diagnosis of type 2 Diabetes.
  • Patients at risk of malnutrition detected by validated screening tools or with DRM diagnosed by GLIM criteria.
  • Patients who have been prescribed 1-2 bottles/day of Resource® Diabet Plus following the conditions of use of its technical data sheet, in the last 2 years, with at least 24 weeks of evolution recorded in the clinical history.
  • Patients who have Hb1Ac data in the medical record on the index date and during evolution.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Patients who required any other type of nutritional supplementation during the study period (parenteral/enteral).
  • Patients with severe renal insufficiency ( \< 30mL/min/1.73m2) at the time of selection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
59 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with T2DM with malnutrition or at risk, who were prescribed: Resource® Diabet Plus
06

What researchers measure

Primary outcomes

  1. Glycaemic control

    Changes in HbA1c, meaning a percentage less than 7, good glycaemic control.

    Time frame: In 12 and 24 weeks from baseline visit

Secondary outcomes

  1. Metabolic control

    Changes in total cholesterol, HDL, LDL and triglycerides. Calculating the number and percentage of patients who increase, decrease or maintain them and those who achieve good metabolic control (defined as: total cholesterol\<185mg/dL, HDL\>40mg/dL, LDL\<100mg/dL and triglycerides\<150mg/dL).

    Time frame: In 12 and 24 weeks from baseline visit

  2. Nutritional and functional status

    Changes in GLIM criteria, arm circumference, calf circumference and prehensile strength

    Time frame: In 12 and 24 weeks from baseline visit

  3. Gastrointestinal tolerance

    By monitoring gastrointestinal symptomatology

    Time frame: In 12 and 24 weeks from baseline visit

  4. Healthcare resource use and associated costs

    Data will be collected on hospitalisations, emergency department visits and specialist visits (all of which are related to malnutrition) for patients during the 24 weeks of treatment. Changes in the patient's anti-diabetic medication, if any, will also be collected. The cost will be calculated by extrapolating each resource to the cost as listed in eSalud and BOT PLUS

    Time frame: During 24 weeks from baseline visit

07

Study locations

4 sites
  • Hospital Universitario Insular de Gran Canaria
    Las Palmas de Gran Canaria, Spain
  • Hospital Clínico Universitario Virgen de la Arrixaca
    Murcia, Spain
  • Hospital Universitario Nuestra Señora de la Candelaria
    Santa Cruz de Tenerife, Spain
  • Hospital Universitario Virgen Macarena
    Seville, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Jul 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 10, 2025
StartActual
Apr 23, 2025
Primary completionActual
Jul 13, 2025
CompletionActual
Jul 13, 2025
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06866366
Lead sponsor
Outcomes'10
Collaborators
Nestlé Health Science Spain
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Apr 23, 2025
Primary completion
Jul 13, 2025
Completion
Jul 13, 2025
Last update
Oct 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion